Entering text into the input field will update the search result below

CSLLY CSL Limited
Stock Price & Overview

$81.730.34 (+0.42%)4:00 PM 09/26/23
OTCQX | $USD | Market Close

Charts

FFO (FWD)
PE
Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Volume
Prev. Close

Quant Ranking

Ratings Summary

Now6M ago
SA Analysts
Not CoveredRating: Not Covered
Wall Street
Not CoveredRating: Not Covered
Quant
Not CoveredRating: Not Covered

Ratings Summary

SA Analysts
Wall Street
Quant

See CSLLY ratings with Premium.

Company Profile

CSL Limited logo
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
Employees
32,065
Founded
1916
Address
  • 655 Elizabeth Street
  • Melbourne, VIC, 3000
  • Australia
Phone Number
61 3 9389 1911
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.